Stealth BioResubmits Rare Disease Drug Application Amid FDA Challenges
TL;DR
Stealth BioTherapeutics disclosed an FDA rejection letter to rally support for its experimental drug for Barth syndrome, a rare disease affecting about 150 people in the U.S., amid ongoing struggles to meet regulatory requirements and concerns over the company's future.
Topics:businesshealthcare#barth-syndrome#fda-rejection#healthcare#rare-disease#regulatory-approval#stealth-biotherapeutics
- Stealth BioTherapeutics discloses FDA rejection letter in effort to rally support for rare disease drug statnews.com
- Stealth Bio submits third FDA application for rare disease candidate Fierce Biotech
- Inside Elamipretide’s CRL: Clinical And Surrogate Evidence Deficiencies, And A Path Forward insights.citeline.com
- STEALTH BIOTHERAPEUTICS RESUBMITS NEW DRUG APPLICATION FOR ELAMIPRETIDE FOR THE TREATMENT OF BARTH SYNDROME Morningstar
- Stealth resubmits ultra-rare disease drug to FDA; Boehringer’s retinal deal Endpoints News
Want the full story? Read the original reporting
Read on statnews.com